The clinical significance of partial chromosome 3 alteration in uveal melanoma is still not clear. Also, the reported frequencies vary considerably in the published literature from 0 to 48%. The aims of the following study were to identify the frequency, molecular pathology and potential clinical significance of partial chromosome 3 alteration in uveal melanoma. We studied 47 uveal melanomas with an average follow-up of 36 months. Of these, 14 had confirmed metastasis. Allelic imbalance/loss of heterozygosity was studied using microsatellite markers on chromosome 3 enriched in markers located in the previously reported smallest regions of deletion overlap. Chromosomal alterations were assessed by conventional cytogenetics or comparative genomic hybridization (CGH) in a subset of patients. Utilizing genotyping, partial chromosome 3 alteration was detected in 14/47 tumors (30%). In the 23 tumors with available cytogenetic/CGH, partial chromosome 3 alteration was detected in 8/23 (38%) and was caused by both gains (4/8) and losses (4/8) of chromosome 3 with high frequency of complex chromosome 3 aberrations detected by cytogenetics. Out of the 14 tumors with confirmed metastasis, only 1 showed partial chromosome 3 alteration and the remaining showed monosomy 3. By limiting the aggressive disease marker to monosomy 3, genotyping showed 93% sensitivity and 67% specificity for detection of aggressive uveal melanoma. In conclusion, partial chromosome 3 alterations are common in uveal melanoma and mostly caused by complex cytogenetic changes leading to partial gains and/or partial losses of chromosome 3. Partial chromosome 3 alteration is not likely to be associated with highly aggressive uveal melanoma that metastasizes within the first 3 years after treatment. Microsatellite-based genotyping of chromosome 3 is highly sensitive for detection of aggressive uveal melanoma. Modern Pathology (2011) 24, 954-962;
Monosomy of chromosome 3 is one of the most common genetic alterations in uveal melanoma with reported frequencies ranging between 30 and 50%. 1, 2 The strong association between monosomy 3 and short survival, first reported by Prescher et al, 3 has been well confirmed. [4] [5] [6] [7] These studies have also shown that metastasis in the absence of monosomy 3 is quite rare. Based on such findings, monosomy 3 is currently being used in many clinical centers as a prognostic marker to identify aggressive uveal melanomas. 1, 2, 8 Contrary to the well-documented clinical significance of monosomy 3, little is known about the clinical significance of partial chromosome 3 alterations in uveal melanoma. Two different approaches have been followed for analysis of partial chromosome 3 alterations in published literature. Some investigators excluded these lesions from their analysis based on the likelihood that they represent a different clinical subgroup, 4, 9 whereas others grouped them with monosomy 3. 10 The frequency of partial chromosome 3 alteration in uveal melanoma varies markedly in the published reports from 0 to 48% (Table 1) . 4, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] Although the vast majority of authors considered that it is caused by small deletions, 4, 15, 17, 18, 20 it should be noted that genotyping, which was utilized by most of these reports, cannot reliably differentiate between deletions and other molecular mechanisms causing allelic imbalances, including mitotic recombination, aneuploidy and amplification. 21 Few reports showed that partial chromosome 3 gains 14 and unbalanced translocations 15 could be involved in the pathogenesis of partial chromosome 3 alteration in uveal melanoma.
The aims of this study were to identify the frequency, clinical significance and potential molecular pathogenesis of partial chromosome 3 alteration in uveal melanoma.
Materials and methods

Samples
Primary uveal melanoma samples were collected from patients who underwent enucleation as the only treatment for their primary tumors at the Department of Ophthalmology, Ohio State University. A total of 47 tumors were included. The study was carried out in accordance with the protocol approved by the institutional review board . Table 2 summarizes the clinical data of the patients included in the study.
DNA Extraction and Genotyping
Tumor DNA was extracted from fresh frozen tumor tissue (39 samples) or from archival material (8 samples). Non-tumor DNA was extracted from either the peripheral blood lymphocytes (34 samples) or from nearby nontumor tissue (13 samples) using DNeasy tissue kit (Qiagen, Valencia, CA, USA). The DNA integrity was assessed using minigel electrophoresis. Extracted DNA was stored at 4 1C until the time of experiments. Genotyping was carried out using 16 microsatellite markers on chromosome 3, with 8 on each chromosome arm. Also, 12 additional markers were utilized in samples with partial chromosome 3 alterations. Microsatellite markers utilized were enriched in markers located within the smallest regions of overlap on chromosome 3 reported by other investigators. 15, 17, 18 All genotyping markers were fluorescent labeled and either obtained from a commercial supplier (Research Genetics, Carlsbad, CA, USA) or custom made (SIGMA, St Louis, MO, USA) utilizing reported primer sequences (http://genome.ucsc. edu). Custom-made primers were labeled at the 5 0 end with either FAM or HEX fluorescent dyes. Genotyping was carried out at the Nucleic Acids Shared Resource, Comprehensive Cancer Center, Ohio State University. Briefly, fluorescently labeled PCR products were loaded in 7 ml hi-di formamide containing 1.2% LIZ500 size standard and were run on 3730 DNA analyzers. The data were analyzed using GeneMapper v3.5 software (Applied Biosystems, Foster City, CA, USA).
The allelic imbalance factor was determined by calculating the ratio of allele heights for both the normal (N) and tumor (T) sample, and then the tumor ratio was divided by the normal ratio ¼ (T1:T2/N1:N2) as previously suggested. 22, 23 To obtain positive ratios, T1 was selected to be the highest of the two alleles. Loss of heterozygosity was defined as total loss of one allele at a constitutional heterozygous locus 22 or an allelic imbalance factor of Z5. This ratio represents total loss of an allele observed in at least 80% of the tumor cells. Allelic imbalance was defined as a skewed intensity ratio between two alleles at a locus in the tumor compared with the normal DNA. 22 We selected a threshold of allelic imbalance factor of 41.5 for scoring regions with allelic imbalance. This ratio is equivalent to loss of an allele observed in at least 33% of the tumor cells.
Conventional Cytogenetics
Karyotyping was carried out at the Cancer Cytogenetics Laboratory, Department of Pathology, Ohio State University according to routine protocols. Karyotyping was carried out for all prospectively collected tumors with sufficient amount of tumor tissue, a total of 20 tumors. Briefly, sterile collected tumor samples were finely minced and treated with collagenase for 1-4 h, until the cells were dissociated. The dissociated cells were cultured in RPMI-1640 (Gibco Invitrogen, Grand Island, NY, USA) þ 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA), supplemented with L-glutamine, penicillin, streptomycin and insulin-transferrinselenium (Gibco Invitrogen) and in MEM (Gibco Invitrogen) þ 10% fetal bovine serum supplemented with penicillin, streptomycin, L-glutamine and bone marrow condiment (BMC; Fisher Scientific, Houston, TX, USA). They were cultured on coverslips and in flasks until partially confluent. Harvest, GTW-banding and analysis were by standard laboratory procedures.
Comparative Genomic Hybridization (CGH)
CGH analysis was performed on 12 retrospectively collected tumors with available frozen tissue according to a published protocol 24 using a CGH nick translation labeling kit (Vysis, Downers Grove, IL, USA). Normal reference DNA was labeled with Texas Red-5-dUTP (Applied Biosystems) and tumor DNA with Fluorescein-12-dUTP (Applied Biosystems). Hybridization of normal female DNA against normal male DNA was used as a negative control. CGH images were acquired with a cooled CCD camera attached to a Zeiss Axioplan 2 epifluorescence microscope, and analyzed using ISIS software (version 1.5.5) from Meta-Systems. We used fixed thresholds of 41.15 for gains and o0.85 for losses based on a two-color control male-to-female hybridization experiment. Data from at least 10 representative images of each chromosome were combined to generate an average ratio profile reflecting the relative copy number changes in test DNA. 24 
Statistical Analysis
Statistical analysis was carried out using STATA version 10 and GB-STAT software. Fisher's exact test was conducted to compare predictors of metastasis across molecular genetic prognostic markers, as well as other clinical prognostic factors such as gender, cell type, tumor size and extrascleral extension. Diagnostic accuracy calculations (sensitivity, specificity, positive and negative predictive values and likelihood ratios) were carried out on patients followed up for at least 36 months or with confirmed metastasis (total 32 participants). Kaplan-Meier curves were plotted to compare the median survival 
Results
Frequency of Partial Chromosome 3 Alteration in Uveal Melanoma
Genotyping identified monosomy 3 with all informative markers showing allelic imbalance/loss of heterozygosity in 26/47 (55%) of the samples included in the study. Allelic imbalances involving only parts of chromosome 3 with the remaining parts showing retention of heterozygosity was identified in 14 (30%) tumors ( Figure 1 ). Heterodisomy of chromosome 3 with all the markers showing retention of heterozygosity was detected in 7 (15%) tumors. Similar frequencies were observed in the subset of samples with available cytogenetics and CGH. Of the 11 samples with available cytogenetics, monosomy 3 was detected in 6 samples (55%), partial chromosome 3 alteration in 3 samples (27%) and heterodisomy 3 in 2 samples (18%) ( Table 3) . Of the 12 samples with available CGH, 7 samples (58%) showed monosomy 3, 4 samples showed partial chromosome 3 alterations (33%) and 1 sample showed disomy of chromosome 3 (8%).
Cytogenetics and CGH confirmed partial chromosome 3 alterations observed by genotyping in all but one of the 23 samples studied (Tables 3 and 4 ). In that sample, UM8004, genotyping identified partial chromosome 3 alteration in the form of allelic imbalance in markers from 3q13 to 3q27, whereas the rest of markers showed retention of heterozygosity. Cytogenetics revealed two normal chromosomes 3, with a marker chromosome suggesting that the marker chromosome likely contains part of chromosome 3.
Molecular Pathology of Partial Chromosome 3 Alteration in Uveal Melanoma
Chromosomal status, either by cytogenetics (ie, karyotyping) or CGH, was available in 8 of 14 samples with partial allelic imbalance/loss of heterozygosity. In four of these eight cases, partial losses were the cause, whereas in the remaining four cases gains of additional material were the cause of allelic imbalances of chromosome 3. Cytogenetics revealed chromosomal rearrangement involving chromosome 3 in three out of the four samples with partial chromosome 3 alterations. In the remaining sample, UM8004, no alteration of chromosome 3 was identified but a marker chromosome was detected (Table 3 ). The majority, 12/14, of tumors with partial chromosome 3 alterations showed an allelic imbalance factor of o1.7, indicating genetic alteration in o41% of the tumor cells. Only three tumors with partial chromosome 3 alterations showed areas with allelic imbalance factor of Z5. This was contrary to tumors with monosomy 3 where the majority 21/26 showed either total loss of an allele or an allelic imbalance factor of Z5, indicating that the genetic alteration existed in 480% of the tumor cells. The difference was statistically significant (Fisher's exact test, Po0.0001). This observation suggests that in the majority of tumors with partial chromosome 3 alteration, the frequency of tumor heterogeneity, including tumor cells lacking genetic alteration in chromosome 3, is much higher than in monosomy 3 tumors.
Clinical Significance of Partial Chromosome 3 Alterations
The clinical significance of partial chromosome 3 alteration was assessed in a subset of patients with confirmed metastasis (14 patients) or a clinical followup of at least 36 months (additional 18 patients), using metastasis as the marker for aggressive disease. Of the 14 patients with confirmed metastasis, only one patient showed partial chromosome 3 alteration with loss of chromosome material on both the p and q arms (Figure 2 ). The difference in the incidence of metastasis between patients with monosomy 3 (13/ 19) and partial chromosome 3 alteration (1/9) was statistically significant (P ¼ 0.005, Fisher's exact test). Also, Kaplan-Meier analysis showed a significant association of monosomy 3, but not partial chromosome 3 alteration, with aggressive disease (log rank Partial chromosome 3 in uveal melanoma test, P ¼ 0.01, Figure 3 ). Of the eight tumors with partial chromosome 3 alteration and 436 months of metastasis-free survival (mean 67 months, range 39-119 months), 3 showed partial gains and 5 had partial losses. Tumors from four of the patients with partial loss showed allelic imbalance in, or nearby, the smallest region of deletion overlap previously reported in uveal melanoma. We also assessed the sensitivity and specificity of genotyping for detection of aggressive disease (Table 5 ). Combining monosomy 3 and partial chromosome 3 alterations as markers of tumor aggressiveness yielded 100% sensitivity but only 28% specificity for prediction of patients who developed metastasis. Limiting the assay to monosomy 3 with exclusion of partial chromosome 3 alterations slightly diminished the sensitivity to 93% but improved the assay specificity to 67%, whereas inclusion of samples with partial chromosome 3 alterations with areas of allelic imbalance factor of Z5 (two tumors) showed 100% sensitivity and 61% specificity for detection of aggressive disease. These results suggest that the majority of partial chromosome 3 alterations are not associated with aggressive disease.
Other clinical prognostic factors such as tumor size, tumor location, extrascleral extension and cell type were not significantly associated with tumor aggressiveness (Table 6 ).
Discussion
The frequency of partial change in uveal melanoma varies considerably in the published literature (Table 1) . Also, its clinical significance is still largely unknown. With the increasing utilization of molecular genetic testing for prediction of aggressive uveal melanoma, especially those based on the status of chromosome 3, understanding the frequency and clinical significance of partial chromosome 3 alterations is crucial for proper management of these patients. Our results indicate that the majority of partial chromosome 3 alterations, especially the cases due to gains of chromosomal materials, are not associated with aggressive disease. Only 1 of the 14 tumors with confirmed metastasis showed partial chromosome 3 alteration, whereas the remaining aggressive tumors showed allelic losses of all the markers on chromosome 3. The partial chromosome 3 case with metastatic disease was rather unique, with a bi-lobed tumor showing molecular genetic heterogeneity with monosomy 3 in one of the two tumor lobes whereas the other part of the tumor showed partial chromosome 3 loss (Figure 2) .
There are few reports of metastatic uveal melanoma showing partial chromosome 3 alterations. 4, 9, 15 Utilizing genotyping, Scholes et al 4 reported one case who died of metastatic disease; however, no further information was presented as the authors excluded all partial chromosome 3 cases from their detailed analysis. Cross et al, 15 also utilizing genotyping, reported one case with partial chromosome 3 involving the 3pter-3q12 region who died of metastatic disease. Conventional cytogenetics of that case showed a near-triploid karyotype with two apparently normal copies of chromosome 3 and several marker chromosomes, 15 suggesting a chromosome 3 parental isodisomy with additional material on chromosome 3. In that study, two additional cases with partial chromosome 3 alterations were metastasis free for 60 months, whereas another two were metastasis free for 23 months. 15 Trolet et al, 9 using array CGH, reported four cases of partial chromosome 3 losses who developed metastatic disease and several metastatic uveal melanoma lesions with partial chromosome 3 losses. The apparent discrepancy between the lack of association between partial chromosome 3 alterations and metastatic disease in our study and that of Trolet et al 9 could be because of the relative smaller sample size in our study or to our relative short follow-up duration. As the vast majority of metastases from uveal melanomas occur during the first 3 years after treatment of the primary tumor, 25 studies utilizing 3-year follow-up period, similar to ours, should identify highly aggressive, rapidly metastasizing tumors. It is worth noting that the original publications linking monosomy 3 to aggressive uveal melanoma utilized 3-year follow-up duration. 3, 26 Also, studies linking gene expression-based molecular classifiers to tumor aggressiveness utilized similar follow-up duration. 12 The unusual high frequency of metastasizing disomy 3 tumors reported by Trolet et al 9 could be related to the followup duration that was not specified in their report. 9 It is worth noting that we identified partial chromosome 3 alteration in the metastatic lesion of a patient who developed metastatic disease 20 years after treatment of the primary tumor (data not shown). Whether the molecular genetics of rapidly metastatic uveal melanoma is different from the slowly metastatic disease still remains to be investigated.
Our study indicates that the frequency of partial chromosome 3 alteration is rather high in uveal melanoma. However, such frequency varies widely in the published literature and ranges from 0 to 48% (Table 1 ). Potential explanations of such variation include the methodology utilized, threshold for detecting genetic alteration, size of the tissue fragment studied, sample fixation, difference in ethnicity, tumor size, tumor heterogeneity or a combination of any of these factors. For example, the marked variation of the frequency of partial chromosome 3 alteration between the original report of Parrella et al 19 (8.5% ) and their later report 17 (34.7%) utilizing the same samples was because of the inclusion of a considerably larger number of genotyping markers in their later study. Similarly, the utilization of different techniques and different thresholds for assessment of the genetic alteration could explain the large difference between the 5% of partial chromosome 3 alteration reported by Scholes et al 4 in their report utilizing genotyping, and the high frequency ranging from 28.8 to 48% reported in their later study on the same samples utilizing multiplex ligation-dependent probe amplification.
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Tumor heterogeneity [27] [28] [29] and the sensitivity of the molecular technique to identify such heterogeneity, including the threshold utilized for detection of genomic alteration, are additional factors explaining variation in the frequency of partial chromosome 3 alteration between different studies. It is worth Partial chromosome 3 in uveal melanoma noting that in the majority (80.7%) of our monosomy 3 cases, we observed either total loss of an allele or an allelic imbalance factor of Z5, indicating that the genetic alteration existed in 480% of the tumor cells. This could be because of either deletion of one copy of chromosome 3 or loss and reduplication leading to acquired parental isodisomy. Such genetic change could be easily detected using various molecular techniques. On the other hand, the majority of cases with partial chromosome 3 alteration (85.7%) showed low allelic imbalance factor (o1.7), indicating significant heterogeneity of the tumors. Molecular techniques and sampling methodologies that include tumor DNA obtained from a relatively large portion of tumor tissue, such as whole tissue sections, are more capable of detecting tumor heterogeneity compared with methods utilizing only small portion of tumor tissues, such as needle biopsy or small fragments from snap-frozen tumor tissues. The molecular pathogenesis of partial chromosome 3 alterations in uveal melanoma is largely believed to be caused by small deletions. 4, 15, 17, 18, 20 Based on that, several smallest regions of deletion overlap have been reported. 15, 17, 18 These areas include 3p24-26, 3p11-14,3q ( ) . It has been suggested that such smallest regions of deletion overlap are the location of tumor-suppressor genes important in the pathogenesis of metastasizing uveal melanoma. It should be noted that of the three reports defining these regions, only two utilized a combination of copy number alteration and allelic imbalances, 15, 18 whereas the third utilized only genotyping. 17 Samples with small gains could bias the assessment as genotyping cannot differentiate between areas of gains and losses at low allelic imbalance factor thresholds. In fact, several of our cases with confirmed partial gains showed allelic imbalances in the reported smallest region of deletion overlap by genotyping.
Our study indicates the high sensitivity of microsatellite-based genotyping for detection of highly aggressive uveal melanoma. Similar results were reported by other investigators utilizing singlenucleotide polymorphism. 13 Microsatellite genotyping is readily available in the majority of clinical molecular laboratories and can be adapted for clinical testing. It is worth noting that our study, similar to the vast majority of other reports on partial chromosome 3, utilized only uveal melanoma treated by enucleation. Further validation of our findings including studies of molecular genetic changes in biopsied small-and medium-sized tumors is recommended.
In conclusion, our results suggest that partial chromosome 3 alteration is common in uveal melanoma. The molecular mechanisms for such changes include complex chromosomal re-arrangements, partial gains and partial deletions. The majority of partial chromosome 3 alterations are not associated with metastatic disease, in particular, rapidly aggressive tumors. 
